FR3037959A1 - - Google Patents

Download PDF

Info

Publication number
FR3037959A1
FR3037959A1 FR1555750A FR1555750A FR3037959A1 FR 3037959 A1 FR3037959 A1 FR 3037959A1 FR 1555750 A FR1555750 A FR 1555750A FR 1555750 A FR1555750 A FR 1555750A FR 3037959 A1 FR3037959 A1 FR 3037959A1
Authority
FR
France
Prior art keywords
group
branched
linear
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR1555750A
Other languages
English (en)
French (fr)
Other versions
FR3037959B1 (fr
Inventor
Balazs Balint
Marton Csekei
Zoltan Szabo
Zoltan Szlavik
Andras Kotschy
Maia Chanrion
Olivier Geneste
I-Jen Chen
James Edward Paul Davidson
James Brooke Murray
Szabolcs Sipos
Levente Ondi
Agnes Proszenyak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Les Laboratoires Servier SAS
Priority to FR1555750A priority Critical patent/FR3037959B1/fr
Priority to UY0001036734A priority patent/UY36734A/es
Priority to KR1020187002027A priority patent/KR102782071B1/ko
Priority to US15/738,186 priority patent/US10323041B2/en
Priority to HK18113624.7A priority patent/HK1254656A1/zh
Priority to TNP/2017/000524A priority patent/TN2017000524A1/en
Priority to PT167308543T priority patent/PT3313817T/pt
Priority to MX2017016995A priority patent/MX381707B/es
Priority to CN201680048560.1A priority patent/CN108137497B/zh
Priority to PCT/EP2016/064418 priority patent/WO2016207217A1/en
Priority to TW105119604A priority patent/TW201712006A/zh
Priority to CA2990084A priority patent/CA2990084C/en
Priority to GEAP201614681A priority patent/GEP20207056B/en
Priority to NZ738471A priority patent/NZ738471B2/en
Priority to GEAP201914681A priority patent/GEP20197056B/en
Priority to CR20170575A priority patent/CR20170575A/es
Priority to SI201631022T priority patent/SI3313817T1/sl
Priority to HRP20201782TT priority patent/HRP20201782T1/hr
Priority to RU2018102368A priority patent/RU2760554C1/ru
Priority to PL16730854T priority patent/PL3313817T3/pl
Priority to JP2017566289A priority patent/JP6741699B2/ja
Priority to LTEP16730854.3T priority patent/LT3313817T/lt
Priority to AU2016282828A priority patent/AU2016282828B2/en
Priority to MA42230A priority patent/MA42230B1/fr
Priority to RS20201419A priority patent/RS61179B1/sr
Priority to DK16730854.3T priority patent/DK3313817T3/da
Priority to EP16730854.3A priority patent/EP3313817B1/en
Priority to CU2017000163A priority patent/CU24466B1/es
Priority to JOP/2016/0127A priority patent/JO3674B1/ar
Priority to EA201890126A priority patent/EA033566B1/ru
Priority to HUE16730854A priority patent/HUE051877T2/hu
Priority to PE2017002717A priority patent/PE20181491A1/es
Priority to MDE20180438T priority patent/MD3313817T2/ro
Priority to UAA201800621A priority patent/UA122498C2/uk
Priority to ES16730854T priority patent/ES2831749T3/es
Priority to ARP160101880A priority patent/AR105102A1/es
Publication of FR3037959A1 publication Critical patent/FR3037959A1/fr
Application granted granted Critical
Publication of FR3037959B1 publication Critical patent/FR3037959B1/fr
Priority to CONC2017/0012832A priority patent/CO2017012832A2/es
Priority to SV2017005589A priority patent/SV2017005589A/es
Priority to PH12017502315A priority patent/PH12017502315B1/en
Priority to CL2017003205A priority patent/CL2017003205A1/es
Priority to ECIEPI201783003A priority patent/ECSP17083003A/es
Priority to ZA2017/08562A priority patent/ZA201708562B/en
Priority to IL256375A priority patent/IL256375B/en
Priority to US16/394,308 priority patent/US10618909B2/en
Priority to CY20201101170T priority patent/CY1123645T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR1555750A 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related FR3037959B1 (fr)

Priority Applications (45)

Application Number Priority Date Filing Date Title
FR1555750A FR3037959B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY0001036734A UY36734A (es) 2015-06-23 2016-06-16 Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
KR1020187002027A KR102782071B1 (ko) 2015-06-23 2016-06-22 신규한 바이사이클릭 유도체, 이의 제조를 위한 방법 및 이를 함유하는 약학적 조성물
US15/738,186 US10323041B2 (en) 2015-06-23 2016-06-22 Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
HK18113624.7A HK1254656A1 (zh) 2015-06-23 2016-06-22 新的二环衍生物、其制备方法以及含有它们的药物组合物
TNP/2017/000524A TN2017000524A1 (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PT167308543T PT3313817T (pt) 2015-06-23 2016-06-22 Derivados bicíclicos, um processo para a sua preparação e composições farmacêuticas que os contêm
MX2017016995A MX381707B (es) 2015-06-23 2016-06-22 Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CN201680048560.1A CN108137497B (zh) 2015-06-23 2016-06-22 新的二环衍生物、其制备方法以及含有它们的药物组合物
PCT/EP2016/064418 WO2016207217A1 (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TW105119604A TW201712006A (zh) 2015-06-23 2016-06-22 新的雙環衍生物，其製備之方法及含其之醫藥組成物
CA2990084A CA2990084C (en) 2015-06-23 2016-06-22 Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201614681A GEP20207056B (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ738471A NZ738471B2 (en) 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914681A GEP20197056B (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CR20170575A CR20170575A (es) 2015-06-23 2016-06-22 Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen.
SI201631022T SI3313817T1 (sl) 2015-06-23 2016-06-22 Biciklični derivati, postopek njihove priprave in farmacevtski sestavki, ki jih vsebujejo
HRP20201782TT HRP20201782T1 (hr) 2015-06-23 2016-06-22 Biciklički derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
RU2018102368A RU2760554C1 (ru) 2015-06-23 2016-06-22 Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
PL16730854T PL3313817T3 (pl) 2015-06-23 2016-06-22 Bicykliczne pochodne, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
JP2017566289A JP6741699B2 (ja) 2015-06-23 2016-06-22 新規な二環式誘導体、それらを調製するためのプロセス及びそれらを含有する医薬組成物
LTEP16730854.3T LT3313817T (lt) 2015-06-23 2016-06-22 Bicikliniai dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
AU2016282828A AU2016282828B2 (en) 2015-06-23 2016-06-22 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MA42230A MA42230B1 (fr) 2015-06-23 2016-06-22 Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
RS20201419A RS61179B1 (sr) 2015-06-23 2016-06-22 Biciklični derivati, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
DK16730854.3T DK3313817T3 (da) 2015-06-23 2016-06-22 Bicycliske derivater, fremgansmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
EP16730854.3A EP3313817B1 (en) 2015-06-23 2016-06-22 Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CU2017000163A CU24466B1 (es) 2015-06-23 2016-06-22 Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen
JOP/2016/0127A JO3674B1 (ar) 2015-06-23 2016-06-22 مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201890126A EA033566B1 (ru) 2015-06-23 2016-06-22 Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
HUE16730854A HUE051877T2 (hu) 2015-06-23 2016-06-22 Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
PE2017002717A PE20181491A1 (es) 2015-06-23 2016-06-22 Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MDE20180438T MD3313817T2 (ro) 2015-06-23 2016-06-22 Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
UAA201800621A UA122498C2 (uk) 2015-06-23 2016-06-22 Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
ES16730854T ES2831749T3 (es) 2015-06-23 2016-06-22 Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
ARP160101880A AR105102A1 (es) 2015-06-23 2016-06-23 Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CONC2017/0012832A CO2017012832A2 (es) 2015-06-23 2017-12-13 Compuestos derivados de d-fenilalanina - n - sustituidos con bicíclicos aromáticos, método de preparación de los mismos y composiciones farmacéuticas que los contienen
SV2017005589A SV2017005589A (es) 2015-06-23 2017-12-13 Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PH12017502315A PH12017502315B1 (en) 2015-06-23 2017-12-14 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CL2017003205A CL2017003205A1 (es) 2015-06-23 2017-12-14 Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECIEPI201783003A ECSP17083003A (es) 2015-06-23 2017-12-15 Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
ZA2017/08562A ZA201708562B (en) 2015-06-23 2017-12-15 New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
IL256375A IL256375B (en) 2015-06-23 2017-12-18 History of new cyclics, process for their preparation and pharmaceutical preparations containing them
US16/394,308 US10618909B2 (en) 2015-06-23 2019-04-25 Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CY20201101170T CY1123645T1 (el) 2015-06-23 2020-12-10 Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555750A FR3037959B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
FR3037959A1 true FR3037959A1 (cg-RX-API-DMAC10.html) 2016-12-30
FR3037959B1 FR3037959B1 (fr) 2017-08-04

Family

ID=54356456

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1555750A Expired - Fee Related FR3037959B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (42)

Country Link
US (2) US10323041B2 (cg-RX-API-DMAC10.html)
EP (1) EP3313817B1 (cg-RX-API-DMAC10.html)
JP (1) JP6741699B2 (cg-RX-API-DMAC10.html)
KR (1) KR102782071B1 (cg-RX-API-DMAC10.html)
CN (1) CN108137497B (cg-RX-API-DMAC10.html)
AR (1) AR105102A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016282828B2 (cg-RX-API-DMAC10.html)
CA (1) CA2990084C (cg-RX-API-DMAC10.html)
CL (1) CL2017003205A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017012832A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170575A (cg-RX-API-DMAC10.html)
CU (1) CU24466B1 (cg-RX-API-DMAC10.html)
CY (1) CY1123645T1 (cg-RX-API-DMAC10.html)
DK (1) DK3313817T3 (cg-RX-API-DMAC10.html)
EA (1) EA033566B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP17083003A (cg-RX-API-DMAC10.html)
ES (1) ES2831749T3 (cg-RX-API-DMAC10.html)
FR (1) FR3037959B1 (cg-RX-API-DMAC10.html)
GE (2) GEP20207056B (cg-RX-API-DMAC10.html)
HK (1) HK1254656A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20201782T1 (cg-RX-API-DMAC10.html)
HU (1) HUE051877T2 (cg-RX-API-DMAC10.html)
IL (1) IL256375B (cg-RX-API-DMAC10.html)
JO (1) JO3674B1 (cg-RX-API-DMAC10.html)
LT (1) LT3313817T (cg-RX-API-DMAC10.html)
MA (1) MA42230B1 (cg-RX-API-DMAC10.html)
MD (1) MD3313817T2 (cg-RX-API-DMAC10.html)
MX (1) MX381707B (cg-RX-API-DMAC10.html)
PE (1) PE20181491A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017502315B1 (cg-RX-API-DMAC10.html)
PL (1) PL3313817T3 (cg-RX-API-DMAC10.html)
PT (1) PT3313817T (cg-RX-API-DMAC10.html)
RS (1) RS61179B1 (cg-RX-API-DMAC10.html)
RU (1) RU2760554C1 (cg-RX-API-DMAC10.html)
SI (1) SI3313817T1 (cg-RX-API-DMAC10.html)
SV (1) SV2017005589A (cg-RX-API-DMAC10.html)
TN (1) TN2017000524A1 (cg-RX-API-DMAC10.html)
TW (1) TW201712006A (cg-RX-API-DMAC10.html)
UA (1) UA122498C2 (cg-RX-API-DMAC10.html)
UY (1) UY36734A (cg-RX-API-DMAC10.html)
WO (1) WO2016207217A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201708562B (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX385115B (es) * 2017-01-06 2025-03-14 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
IL271475B2 (en) 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
DK3796975T3 (da) 2018-05-22 2023-12-04 Orsobio Inc Sulfonylaminobenzamidderivater
TWI748194B (zh) * 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2021067827A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
US12522606B2 (en) * 2020-01-09 2026-01-13 University Of Washington Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017678A1 (en) * 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2013067260A1 (en) * 2011-11-03 2013-05-10 Genentech, Inc. Bicyclic piperazine compounds
WO2013072694A1 (en) * 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
MX2011006319A (es) 2008-12-18 2011-06-24 Bayer Cropscience Ag Amidas del acido antranilico sustituidas con tetrazol como plaguicidas.
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017678A1 (en) * 2005-08-09 2007-02-15 Eirx Therapeutics Limited Pyrazolo[1,5-a] pyrimidine compounds and pharmaceutical compositions containing them
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2013067260A1 (en) * 2011-11-03 2013-05-10 Genentech, Inc. Bicyclic piperazine compounds
WO2013072694A1 (en) * 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORDEU ET AL: "Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 4, 14 January 2007 (2007-01-14), pages 1659 - 1669, XP005830426, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.12.010 *
KEMNITZER W ET AL: "Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 13, 1 July 2009 (2009-07-01), pages 3536 - 3540, XP026155103, ISSN: 0960-894X, [retrieved on 20090505], DOI: 10.1016/J.BMCL.2009.04.145 *

Also Published As

Publication number Publication date
MX381707B (es) 2025-03-13
SV2017005589A (es) 2018-06-01
JO3674B1 (ar) 2020-08-27
UY36734A (es) 2016-12-30
GEAP201914681A (en) 2019-09-10
PH12017502315A1 (en) 2018-06-25
US20180258098A1 (en) 2018-09-13
MA42230B1 (fr) 2020-11-30
UA122498C2 (uk) 2020-11-25
ECSP17083003A (es) 2018-02-28
RS61179B1 (sr) 2021-01-29
CL2017003205A1 (es) 2018-06-15
EP3313817A1 (en) 2018-05-02
PE20181491A1 (es) 2018-09-18
US20190248805A1 (en) 2019-08-15
CU24466B1 (es) 2020-01-03
CR20170575A (es) 2018-02-20
CA2990084C (en) 2021-04-13
DK3313817T3 (da) 2020-12-14
CA2990084A1 (en) 2016-12-29
HRP20201782T1 (hr) 2021-01-22
FR3037959B1 (fr) 2017-08-04
TW201712006A (zh) 2017-04-01
CU20170163A7 (es) 2018-05-08
GEP20207056B (en) 2020-01-10
JP2018527297A (ja) 2018-09-20
ES2831749T3 (es) 2021-06-09
AR105102A1 (es) 2017-09-06
KR102782071B1 (ko) 2025-03-14
EA201890126A1 (ru) 2018-06-29
CY1123645T1 (el) 2022-03-24
IL256375A (en) 2018-02-28
CN108137497A (zh) 2018-06-08
WO2016207217A1 (en) 2016-12-29
ZA201708562B (en) 2022-06-29
HUE051877T2 (hu) 2021-03-29
US10618909B2 (en) 2020-04-14
NZ738471A (en) 2024-05-31
TN2017000524A1 (en) 2019-04-12
PT3313817T (pt) 2020-11-26
RU2760554C1 (ru) 2021-11-29
PH12017502315B1 (en) 2018-06-25
JP6741699B2 (ja) 2020-08-19
AU2016282828A1 (en) 2018-01-18
SI3313817T1 (sl) 2021-01-29
PL3313817T3 (pl) 2021-04-06
MX2017016995A (es) 2018-09-07
MA42230A (fr) 2018-05-02
CN108137497B (zh) 2021-06-15
KR20180015264A (ko) 2018-02-12
GEP20197056B (en) 2020-01-10
LT3313817T (lt) 2020-11-25
EA033566B1 (ru) 2019-11-05
HK1254656A1 (zh) 2019-07-26
IL256375B (en) 2020-03-31
CO2017012832A2 (es) 2018-03-28
US10323041B2 (en) 2019-06-18
EP3313817B1 (en) 2020-09-16
MD3313817T2 (ro) 2021-01-31
AU2016282828B2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
US10618909B2 (en) Bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2990089C (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
FR3037957A1 (cg-RX-API-DMAC10.html)
RU2745430C1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
FR3015483A1 (fr) Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3052452A1 (cg-RX-API-DMAC10.html)
CN104136399B (zh) 泛素活化酶的吡唑并嘧啶基抑制剂
KR20130122778A (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
OA18891A (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK1254872A1 (zh) 新的二环衍生物、其制备方法以及含有它们的药物组合物
BR112017027470B1 (pt) Derivados bicíclicos, processo para sua preparação, composições farmacêuticas que os contêm, combinação e uso dos mesmos
NZ702851B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20161230

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20230205